Correction: Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma (JAMA Oncology (2015) DOI: 10.1001/jamaoncol.2015.0493);Association between NRAS and BRAF mutational status and melanoma-specific survival among patients with higher-risk primary melanoma

JAMA Oncology

Volumn 1, Issue 3, 2015, Pages 359-368

  Thomas, Nancy E ^a,b   Edmiston, Sharon N ^b   Alexander, Audrey ^b   Groben, Pamela A ^a   Parrish, Eloise ^b   Kricker, Anne ^c   Armstrong, Bruce K ^c   Anton Culver, Hoda ^d   Gruber, Stephen B ^e   From, Lynn ^f   Busam, Klaus J ^g   Hao, Honglin ^b   Orlow, Irene ^g   Kanetsky, Peter A ^h   Luo, Li ⁱ   Reiner, Anne S ^g   Paine, Susan ⁱ   Frank, Jill S ^a   Bramson, Jennifer I ^a   Marrett, Lorraine D ^j   Gallagher, Richard P ^k   Zanetti, Roberto ^l   Rosso, Stefano ^l   Dwyer, Terence ^m,n   Cust, Anne E ^c   Ollila, David W ^a,b   Begg, Colin B ^g   Berwick, Marianne ⁱ   Conway, Kathleen ^b,o   more..

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f WOMEN S COLLEGE HOSPITAL   (Canada)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

ⁱ UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^j CANCER CARE ONTARIO   (Canada)

^k BRITISH COLUMBIA CANCER AGENCY   (Canada)

^l Piedmont Cancer Registry   (Italy)

^m UNIVERSITY OF OXFORD   (United Kingdom)

ⁿ UNIVERSITY OF OXFORD   (United Kingdom)

^o University of North Carolina at Chapel Hill   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; ENZYMOLOGY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOLOGY; KAPLAN MEIER METHOD; MALE; MELANOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MUTATION; NEW SOUTH WALES; ODDS RATIO; PATHOLOGY; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; RISK FACTOR; SKIN NEOPLASMS; TIME FACTOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GTP PHOSPHOHYDROLASES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; NEW SOUTH WALES; ODDS RATIO; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; TIME FACTORS; TUMOR MICROENVIRONMENT; UNITED STATES;

EID: 84987811392     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.1781     Document Type: Erratum

References (51)

1. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417 (6892):949-954.
2. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9(17):6483-6488.
3. Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 2004;64(7):2338-2342.
4. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
5. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet.2012;380(9839):358-365.
6. Flaherty KT, Robert C, Hersey P, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
7. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134-144.
8. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
9. Davar D, Tarhini AA, Kirkwood JM. Adjuvant therapy for melanoma. Cancer J. 2012;18(2):192-202.
10. Broekaert SM, Roy R, Okamoto I, et al. Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res. 2010;23(6):763-770.
11. Nagore E, Requena C, Traves V, et al. Prognostic value of BRAF mutations in localized cutaneous melanoma. J Am Acad Dermatol. 2014;70(5):858-862.
12. Meckbach D, Bauer J, Pflugfelder A, et al. Survival according to BRAF-V600 tumor mutations - an analysis of 437 patients with primary melanoma. PLoS One. 2014;9(1):e86194.
13. Ellerhorst JA, Greene VR, Ekmekcioglu S, et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res. 2011;17(2):229-235.
14. Edlundh-Rose E, Egyházi S, Omholt K, et al. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res. 2006;16(6):471-478.
15. Houben R, Becker JC, Kappel A, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004;3(1):6.
16. Kannengiesser C, Spatz A, Michiels S, et al; EORTC Melanoma group. Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas. Mol Oncol. 2008;1(4):425-430.
17. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res. 2004;10(5):1753-1757.
18. Akslen LA, Angelini S, Straume O, et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J Invest Dermatol. 2005;125(2):312-317.
19. Griewank KG, Murali R, Puig-Butille JA, et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst. 2014;106(9):dju246.
20. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst. 2003;95(24):1878-1890.
21. Devitt B, Liu W, Salemi R, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 2011;24(4):666-672.
22. Wu S, Kuo H, Li WQ, Canales AL, Han J, Qureshi AA. Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma. Cancer Causes Control. 2014;25(10):1379-1386.
23. Begg CB, Hummer AJ, Mujumdar U, et al; GEM Study Group. A design for cancer case-control studies using only incident cases: experience with the GEM study of melanoma. Int J Epidemiol. 2006;35(3):756-764.
24. Begg CB, Hummer A, Mujumdar U, et al; GEM Study Group. Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes Control. 2004;15(9):957-965.
25. Millikan RC, Hummer A, Begg C, et al. Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the Genes Environment and Melanoma Study. Carcinogenesis. 2006;27(3):610-618.
26. Orlow I, Begg CB, Cotignola J, et al; GEM Study Group. CDKN2A germline mutations in individuals with cutaneous malignant melanoma. J Invest Dermatol. 2007;127(5):1234-1243.
27. Murali R, Goumas C, Kricker A, et al; GEM Study Group. Clinicopathologic features of incident and subsequent tumors in patients with multiple primary cutaneous melanomas. Ann Surg Oncol. 2012;19(3):1024-1033.
28. Thomas NE, Kricker A, Waxweiler WT, et al; Genes, Environment, and Melanoma (GEM) Study Group. Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study. JAMA Dermatol. 2014;150(12):1306-1314.
29. Thomas NE, Busam KJ, From L, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J Clin Oncol. 2013;31(33):4252-4259.
30. Piris A, Mihm MC Jr, Duncan LM. AJCC melanoma staging update: impact on dermatopathology practice and patient management. J Cutan Pathol. 2011;38(5):394-400.
31. Elder DE, Gimotty PA, Guerry D. Cutaneous melanoma: estimating survival and recurrence risk based on histopathologic features. Dermatol Ther. 2005;18(5):369-385.
32. Thomas NE, Alexander A, Edmiston SN, et al. Tandem BRAF mutations in primary invasive melanomas. J Invest Dermatol. 2004;122(5):1245-1250.
33. Thomas NE, Edmiston SN, Alexander A, et al. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev. 2007;16(5):991-997.
34. Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol. 2008;144(4):515-521.
35. Tseng WH, Martinez SR. Tumor location predicts survival in cutaneous head and neck melanoma. J Surg Res. 2011;167(2):192-198.
36. Green AC, Baade P, Coory M, Aitken JF, Smithers M. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol. 2012;30(13):1462-1467.
37. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. JAm Stat Assoc. 1999;94(446):496-509.
38. Selvin S. A note on the power to detect interaction effects. In: Kesley J, Marmot M, Stolley P, Vessey M, eds. Statistical Analysis of Epidemiologic Data. New York, NY: Oxford University Press; 1996:213-214.
39. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
40. Hacker E, Hayward NK, Dumenil T, James MR, Whiteman DC. The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. J Invest Dermatol. 2010;130(1):241-248.
41. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma. J Invest Dermatol. 2006;126(1):154-160.
42. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008;5(6):e120.
43. Liu W, Kelly JW, Trivett M, et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol. 2007;127(4):900-905.
44. Estrozi B, Machado J, Rodriguez R, Bacchi CE. Clinicopathologic findings and BRAF mutation in cutaneous melanoma in young adults. Appl Immunohistochem Mol Morphol. 2014;22(1):57-64.
45. Chung KT, Nilson EH, Case MJ, Marr AG, Hungate RE. Estimation of growth rate from the mitotic index. Appl Microbiol. 1973;25(5):778-780.
46. Liu W, Dowling JP, Murray WK, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol. 2006;142(12):1551-1558.
47. Nagore E, Hacker E, Martorell-Calatayud A, et al. Prevalence of BRAF and NRAS mutations in fast-growing melanomas. Pigment Cell Melanoma Res. 2013;26(3):429-431.
48. Mandalà M, Merelli B, Massi D. NRAS in melanoma: targeting the undruggable target. Crit Rev Oncol Hematol. 2014;92(2):107-122.
49. Fargnoli MC, Pike K, Pfeiffer RM, et al. MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol. 2008;128(10):2485-2490.
50. Lee EY, Williamson R, Watt P, Hughes MC, Green AC, Whiteman DC. Sun exposure and host phenotype as predictors of cutaneous melanoma associated with neval remnants or dermal elastosis. Int J Cancer. 2006;119(3):636-642.
51. Richmond-Sinclair NM, Lee E, Cummings MC, et al. Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas. Melanoma Res. 2008;18(5):336-345.